Menu
Recruiting NCT04845217

Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome

Phase I / Phase II Interventional Interstitial Cystitis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Peppermint oil, Coconut Oil.
Who it may be relevant to
Registry conditions: Interstitial Cystitis. Basic parameters: 18 years — 65 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Efficacy of Peppermint Oil in a Randomized, Single-Blind, Placebo Controlled Trial in Women With Interstitial Cystitis/Bladder Pain Syndrome

Overview

The purpose of this study is to assess the use of peppermint oil as a treatment for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).

Detailed description

After being informed about the study and potential risks, all participants will complete validated IC/BPS symptom questionnaires for baseline screening. Once participants meet eligibility requirements and give written informed consent they will be randomized in a 1:1 ratio to peppermint oil (200mg TID) or placebo (also TID). Participants will complete validated IC/BPS questionnaires and follow up surveys over 8 weeks.

Interventions

  • Drug Peppermint oil
    Enteric coated peppermint oil taken by mouth three times daily for 8 weeks.
  • Drug Coconut Oil
    Enteric coated coconut oil taken by mouth three times daily for 8 weeks

Primary outcome measures

  • O'Leary/Sant questionnaire scores [Time frame: 8 weeks]
  • Pelvic Pain and Urgency/Frequency questionnaire scores [Time frame: 8 weeks]
Secondary outcome measures (3)
  • Urine pH [Time frame: 8 weeks]
  • Incidence of urinary tract infections (UTIs) [Time frame: 8 weeks]
  • Additional IC/BPS Treatments received [Time frame: 8 weeks]

Eligibility criteria

Inclusion criteria

  • Women ages 18-65 years old
  • Diagnosed with IC/BPS for at least one month prior to study enrollment

Exclusion criteria

  • Culture proven urinary tract infection within 1 month of randomization
  • Gross hematuria
  • Currently pregnant or breastfeeding
  • Unable to speak and read English
  • History of allergic reaction to peppermint, coconut or enteric coating
  • History of malabsorption syndrome
  • History of gastroparesis
  • History of gastric bypass surgery
  • History of gastrointestinal, genitourinary or pelvic cancer in the last 5 years
  • History of insulin dependent diabetes
  • History of active urinary stone disease

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • Springs Medical Center — Louisville

Identifiers

NCT: NCT04845217 · 21.0286

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗